|
Sign In to gain access to subscriptions and/or personal tools.
|
Lupus, Vol. 6, No. 6,
533-539 (1997)
DOI: 10.1177/096120339700600610
Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies
EF Borba
Division of Rheumatology, São Paulo University Medical School Hospital, São Paulo, SP, Brazil
E. Bonfá
Division of Rheumatology, São Paulo University Medical School Hospital, São Paulo, SP, Brazil
Objective: To determine the influence of systemic lupus erythematosus (SLE), disease activity, and anticardiolipin antibodies (aCL) on lipid profile, in order to identify patients with high risk for coronary artery disease (CAD).
Methods: Fasting lipid profiles were performed in 36 consecutive female SLE patients without any therapy and 30 controls. Exclusion criteria were diabetes mellitus, CAD, liver or thyroid disease, ingestion of lipid-raising drugs, serum creatinine  1.5 mg/dl, and proteinuria 0.5 g/d. Disease activity was measured by SLEDAI.
Results: High levels of VLDL-C and TG and low levels of HDL-C, the 'lupus pattern', were observed in inactive SLE compared to controls (P < 0.05). Active disease enhanced this difference inducing a more striking increase in VLDL-C and TG levels and also a decrease in HDL-C and LDL-C levels compared to inactive SLE patients (P < 0.05), characterizing the 'active lupus pattern'. Moreover, a significant correlation was found between SLEDAI scores and all lipid fractions. Furthermore these lipid abnormalities were particularly associated with vasculitis. Lower HDL-C levels detected in IgG aCL+ patients compared to IgG aCL - patients were not confirmed by two-way analysis of variance which demonstrated that this difference was exclusively caused by disease activity.
Conclusions: Our findings suggest that SLE patients have a lipid profile abnormality which is aggravated by disease activity and may reside in a defect of VLDL metabolism. This pattern of dyslipoproteinemia may increase the risk of developing coronary artery disease.
Key Words: dyslipoproteinemia • systemic lupus erythematosus • anticardiolipin antibodies • lipoproteins • atherosclerosis
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J Frostegard
Systemic lupus erythematosus and cardiovascular disease
Lupus,
May 1, 2008;
17(5):
364 - 367.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A.W.S. de Souza, N.P. Silva, J.F. de Carvalho, V. D'Almeida, M.A.E. Noguti, and E.I. Sato
Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome
Lupus,
October 1, 2007;
16(10):
782 - 787.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. R. BATUCA, P. R. J. AMES, D. A. ISENBERG, and J. DELGADO ALVES
Antibodies toward High-Density Lipoprotein Components Inhibit Paraoxonase Activity in Patients with Systemic Lupus Erythematosus
Ann. N.Y. Acad. Sci.,
June 1, 2007;
1108(1):
137 - 146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Michel, E. Fois, M. Niault, V. Pruneta, B. Godeau, and M. Michel
Severe autoimmune type V hyperlipidemia preceding a systemic lupus erythematosus in a 15 year-old girl
Lupus,
May 1, 2007;
16(5):
378 - 379.
[PDF]
|
|
|
|
|
|
|
J.C. Sachet, E.F. Borba, E. Bonfa, C.G.C. Vinagre, V.M. Silva, and R.C. Maranhao
Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients
Lupus,
April 1, 2007;
16(4):
273 - 278.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C Ayan and V Martin
Systemic lupus erythematosus and exercise
Lupus,
January 1, 2007;
16(1):
5 - 9.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M McMahon, J Grossman, W Chen, and B H Hahn
Inflammation and the pathogenesis of atherosclerosis in systemic lupus erythematosus
Lupus,
November 1, 2006;
15(11_suppl):
59 - 69.
[Abstract]
[PDF]
|
|
|
|
|
|
|
I. N. Bruce
'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus
Rheumatology,
December 1, 2005;
44(12):
1492 - 1502.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I N Bruce
Atherogenesis and autoimmune disease: the model of lupus
Lupus,
September 1, 2005;
14(9):
687 - 690.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Frostegard
Atherosclerosis in Patients With Autoimmune Disorders
Arterioscler. Thromb. Vasc. Biol.,
September 1, 2005;
25(9):
1776 - 1785.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A L. Hayata, E F Borba, E Bonfa, J A. Kochen, and C Goldenstein-Schainberg
The frequency of high/moderate lipoprotein risk factor for coronary artery disease is significant in juvenile-onset systemic lupus erythematosus
Lupus,
August 1, 2005;
14(8):
613 - 617.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Jimenez, M. A. Garcia-Criado, D. Tassies, J. C. Reverter, R. Cervera, M. R. Gilabert, D. Zambon, E. Ros, C. Bru, and J. Font
Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome
Rheumatology,
June 1, 2005;
44(6):
756 - 761.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B Siripaitoon, M Osiri, V Vongthavaravat, S Akkasilpa, and U Deesomchok
The prevalence of dyslipoproteinemia in Thai patients with systemic lupus erythematosus
Lupus,
December 1, 2004;
13(12):
961 - 968.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Bessant, A. Hingorani, L. Patel, A. MacGregor, D. A. Isenberg, and A. Rahman
Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus
Rheumatology,
July 1, 2004;
43(7):
924 - 929.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Wajed, Y. Ahmad, P. N. Durrington, and I. N. Bruce
Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management
Rheumatology,
January 1, 2004;
43(1):
7 - 12.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Delgado Alves, S. Kumar, and D. A. Isenberg
Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome
Rheumatology,
July 1, 2003;
42(7):
893 - 899.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E Svenungsson, G-Z Fei, K Jensen-Urstad, U de Faire, A Hamsten, and J Frostegard
TNF-{alpha}: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease
Lupus,
June 1, 2003;
12(6):
454 - 461.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. Bilora, V. Boccioletti, B. Girolami, E. Zanon, M. Armani, F. Petrobelli, and A. Girolami
Are Antiphospholipid Antibodies an Independent Risk Factor for Atherosclerosis?
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2002;
8(2):
103 - 113.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. Svenungsson, K. Jensen-Urstad, M. Heimburger, A. Silveira, A. Hamsten, U. de Faire, J. L. Witztum, and J. Frostegard
Risk Factors for Cardiovascular Disease in Systemic Lupus Erythematosus
Circulation,
October 16, 2001;
104(16):
1887 - 1893.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S E Lane, K Gaffney, R Y Ball, and T J Marshall
Grand Rounds from International Lupus Centres: A swollen leg unmasks longstanding SLE
Lupus,
January 1, 2001;
10(1):
4 - 8.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L S Tam, E K Li, C W. Lam, and B Tomlinson
Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease
Lupus,
July 1, 2000;
9(6):
413 - 416.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M B Urowitz and D D Gladman
Accelerated atheroma in lupus--background
Lupus,
March 1, 2000;
9(3):
161 - 165.
[Abstract]
[PDF]
|
|
|
|
